EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond

Jane Y Chang iD, Curt Balch, Hyung Suk Oh iD

Viruses · 17.09.2024 · 16 (9) · 1476

DOI: 10.3390/v16091476 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 17.09.2024. Verfasst von Jane Y Chang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ascendant Biotech Inc., Foster City, CA 94404, USA. Hauptthemen laut MEDLINE: Herpes Simplex, Herpes Simplex Virus Vaccines, Vaccination, Simplexvirus. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Herpes simplex virus (HSV) has coevolved with Homo sapiens for over 100,000 years, maintaining a tenacious presence by establishing lifelong, incurable infections in over half the human population. As of 2024, an effective prophylactic or therapeutic vaccine for HSV remains elusive. In this review, we independently screened PubMed, EMBASE, Medline, and Google Scholar for clinically relevant articles on HSV vaccines. We identified 12 vaccines from our literature review and found promising candidates across various classes, including subunit vaccines, live vaccines, DNA vaccines, and mRNA vaccines. Notably, several vaccines—SL-V20, HF10, VC2, and mRNA-1608—have shown promising preclinical results, suggesting that an effective HSV vaccine may be within reach. Additionally, several other vaccines such as GEN-003 (a subunit vaccine from Genocea), HerpV (a subunit vaccine from Agenus), 0ΔNLS/RVx201 (a live-attenuated replication-competent vaccine from Rational Vaccines), HSV 529 (a replication-defective vaccine from Sanofi Pasteur), and COR-1 (a DNA-based vaccine from Anteris Technologies) have demonstrated potential in clinical trials. However, GEN-003 and HerpV have not advanced further despite promising results. Continued progress with these candidates brings us closer to a significant breakthrough in preventing and treating HSV infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpes SimplexHerpes Simplex Virus VaccinesVaccinationSimplexvirusHumansAnimalsVaccines, SubunitVaccines, DNAVaccines, AttenuatedDisease Eradication

Stichwörter der Autor:innen

herpes simplex virus type 1interferon responselive-attenuated vaccinesmRNA vaccinereplication-defective strains

Substanzen

Herpes Simplex Virus VaccinesVaccines, SubunitVaccines, DNAVaccines, Attenuated

Autor:innen und Institutionen

  • Ascendant Biotech Inc., Foster City, CA 94404, USA.
  • Bioscience Advising, Cincinnati, OH 45208, USA.
  • Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.

ORCID-Profile: Jane Y Chang, Hyung Suk Oh

Zitieren

APA

Chang, J. Y., Balch, C., & Oh, H. S. (2024). Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond. Viruses, 16(9), 1476. https://doi.org/10.3390/v16091476

Vancouver

Chang JY, Balch C, Oh HS. Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond. Viruses. 2024;16(9):1476. doi:10.3390/v16091476

BibTeX
@article{Chang2024,
  author = {Chang, Jane Y and Balch, Curt and Oh, Hyung Suk},
  title = {Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond},
  journal = {Viruses},
  year = {2024},
  volume = {16},
  number = {9},
  pages = {1476},
  doi = {10.3390/v16091476}
}
Kostenlos starten →